Aytu BioPharma reports Q2 net income $0.8M; Pediatric revenue up 86% sequentially

AYTU BIOPHARMA, INC

2025-Q2 EPS reported -$0.41 vs consensus -$0.04 ▼ miss (-996.3%)

Net revenue $16.2M, down 13% YoY; ADHD revenue fell 17% to $13.8M, Pediatric rose 12% to $2.4M.
Net income $0.8M ($0.13 basic EPS) vs net loss $0.2M in Q2FY24; adjusted EBITDA $1.3M vs $5.5M.
Sequential prescription growth for both ADHD and Pediatric portfolios, first since Q2FY23.
Cash $20.4M at Dec 31, 2024, flat vs Sep 30; cost savings initiatives to cut at least $2M annually.
Gross margin 66% vs 78% a year ago due to higher-cost ADHD inventory from manufacturing transition.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.